The Journal of Nuclear Medicine最新文献

{"title":"Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data","authors":"Lena M. Unterrainer, Nicolas De Leiris, Marcus Unterrainer, Astrid Delker, Linus Hempel, Zachary Ells, Sophie C. Kunte, Josef Zahner, Adrien Holzgreve, Mathias J. Zacherl, Gabriel T. Sheikh, Jozefina Casuscelli, Julien Leenhardt, Kenneth J. Pienta, Emmanuelle Jacquet, Mathieu Laramas, Jerome Long, Marine Faure, Ghislaine Reboulet, Channing J. Paller, Alexis Mercier, Lilja B. Solnes, Kevin Kiraz, Harun Ilhan, Andrei Gafita, Loïc Djaileb","doi":"10.2967/jnumed.124.269431","DOIUrl":"https://doi.org/10.2967/jnumed.124.269431","url":null,"abstract":"<p>Our objectives were to assess the prognostic value of posttherapy [¹⁷⁷Lu]Lu-PSMA (LuPSMA) SPECT/CT by visual evaluation using RECIP 1.0 during LuPSMA therapy and develop an evidence-based clinical protocol to monitor the efficacy of LuPSMA. <strong>Methods:</strong> Patients with metastatic castration-resistant prostate cancer who received at least 2 LuPSMA cycles between April 2019 and November 2023 were retrospectively included in this study. Pairs of baseline and interim LuPSMA SPECT/CT (SPECT) and PSMA PET/CT (PET) images after 2 therapy cycles were analyzed per visual RECIP 1.0. Changes in prostate-specific antigen (PSA) levels at 12 wk were categorized by Prostate Cancer Working Group Criteria 3 guidelines and combined with RECIP 1.0 reads to determine disease progression using a composite classification method (PSA + RECIP). The primary outcome was the prognostic value of posttherapeutic SPECT by RECIP 1.0 for overall survival (OS). The clinical protocol was developed on the basis of the prognostic accuracy (Harrell concordance index, or C-index) of SPECT versus PET and the combination of SPECT plus PSA (SPECT + PSA) versus the combination of PET plus PSA (PET + PSA). <strong>Results:</strong> Data from 105 patients were evaluated. Progressive disease determined by SPECT was associated with shorter OS compared with stable disease (hazard ratio, 2.5; 95% CI, 1.2–5.3; <em>P</em> = 0.015) and with partial response (hazard ratio, 6.5; 95% CI, 2.7–15.7; <em>P</em> &lt; 0.001). Of the 73 patients who underwent PET after 2 cycles, 7 (10%), 30 (41%), 22 (30%), and 30 (41%) had tumor progression shown by SPECT, PET, SPECT + PSA, and PET + PSA, respectively. The C-index for SPECT was inferior compared with that for PET (0.54 vs. 0.66; <em>P</em> &lt; 0.001), whereas the C-indices for SPECT + PSA and PET + PSA did not differ significantly (0.62 vs. 0.66, respectively; <em>P</em> = 0.07). <strong>Conclusion:</strong> Posttherapeutic LuPSMA SPECT/CT per RECIP 1.0 after 2 therapy cycles was prognostic for OS. LuPSMA SPECT/CT identified significantly fewer patients with RECIP-classified progressive disease; however, SPECT + PSA achieved similar prognostic accuracy to PET + PSA for LuPSMA response evaluation.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143872814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients with Suspected 4-Repeat Tauopathies","authors":"Joachim Brumberg, Nils Schröter, Ganna Blazhenets, M. Aymen Omrane, Christian Volz, Cornelius Weiller, Michel Rijntjes, Lars Frings, Sabine Hellwig, Wolfgang H. Jost, Philipp T. Meyer","doi":"10.2967/jnumed.124.268956","DOIUrl":"https://doi.org/10.2967/jnumed.124.268956","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.268956absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143847085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Long–Axial-Field-of-View PET/CT Cost-Effective? An International Health–Economic Analysis","authors":"Ian Alberts, Stuart More, Karen Knapp, Riccardo Mei, Stefano Fanti, Clemens Mingels, Lorenzo Nardo, Nii Boye Hammond, Harish Nagaraj, Axel Rominger, Gary J.R. Cook, Don Wilson","doi":"10.2967/jnumed.124.269203","DOIUrl":"https://doi.org/10.2967/jnumed.124.269203","url":null,"abstract":"<p>Our aim is to assess the cost-effectiveness of long–axial-field-of-view (LAFOV) versus short–axial FOV (SAFOV) PET/CT systems using international data. <strong>Methods:</strong> Our model compares equipment and operational costs for a PET/CT center and investigates the effect of camera choice (SAFOV vs. LAFOV) and operational models. Variables include scanner, personnel, radiopharmaceuticals, and operational costs. Economic performance was measured as cost per scan per patient, the total maximum number of scans possible, and the incremental cost-effectiveness ratio. The willingness-to-pay threshold (WTPT) was taken as the cost of a PET/CT scan using the baseline scenario. Radiopharmaceutical requirements, radiation dose to staff and patients, and patient time were modeled. <strong>Results:</strong> An LAFOV system can examine as many patients per day (<em>n</em> = 36) as 2 SAFOV systems but requires fewer technologists (4.5 LAFOV vs. 6.8 SAFOV full-time equivalents) and lower activity (12.5 vs. 35.6 GBq/d), resulting in lower personnel doses (0.9 vs. 2.0 mSv/y). For all countries, LAFOV resulted in lowest per-patient scan costs. The most cost-ineffective method was the use of extended hours. Incremental cost-effectiveness ratio analysis strongly favored LAFOV for all countries, including low-income economies, with WTPT met for all jurisdictions. Net monetary benefit was highest for LAFOV. The minimum number of patients needed to meet WTPT for LAFOV was lowest in lower-income countries, suggesting that high throughput or high per-procedure income is not a prerequisite for cost-effective LAFOV usage. <strong>Conclusion:</strong> LAFOV was shown to facilitate higher patient throughput at lower per-patient and total lifetime operational costs and with lower radiopharmaceutical requirements. These data suggest that LAFOV systems are not just suited to well-resourced academic centers but also are an economically attractive solution for community and resource-limited settings.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143847091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semiquantitative PET Parameters Refine Prognosis in CAR T–Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study","authors":"Andrea Farolfi, Beatrice Casadei, Claudio Malizia, Riccardo Ussia, Veronica Rocchi, Andrea Paccagnella, Marianna Gentilini, Cristina Nanni, Lisa Argnani, Pier Luigi Zinzani, Stefano Fanti","doi":"10.2967/jnumed.125.269670","DOIUrl":"https://doi.org/10.2967/jnumed.125.269670","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.269670absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143847092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer","authors":"Justin S. Hachey, Tara D. Viray, Mattia Matasci, Domenico Ravazza, Dario Neri, Jason S. Lewis","doi":"10.2967/jnumed.124.268859","DOIUrl":"https://doi.org/10.2967/jnumed.124.268859","url":null,"abstract":"<p>Triple-negative breast cancer (TNBC) lags behind other breast cancer types in targeted therapeutic and diagnostic imaging agent development, largely due to high disease heterogeneity. Noninvasive imaging is essential for diagnosing and staging TNBC and predicting and measuring treatment response. This study targeted a conserved disease-specific extracellular matrix protein domain (the extra domain A of fibronectin [EDA-FN]), with a monoclonal antibody (F8) to overcome tumor cell marker heterogeneity and develop an imaging agent to detect multiple TNBC subtypes and improve diagnostic capacity. <strong>Methods:</strong> [⁸⁹Zr]Zr-desferrioxamine [DFO]-F8 was synthesized and evaluated in vitro and in vivo for EDA-FN binding capacity to detect TNBC by PET/CT in several preclinical xenograft models. <strong>Results:</strong> [⁸⁹Zr]Zr-DFO-F8 exhibited specific, blockable EDA-FN binding activity in vitro. In vivo experiments demonstrated high tumor uptake in preclinical TNBC xenograft models. [⁸⁹Zr]Zr-DFO-F8 detected EDA-FN in subcutaneous and orthotopic TNBC xenografts and accumulated in aggressive disease concordantly with EDA-FN expression. <strong>Conclusion:</strong> EDA-FN imaging with [⁸⁹Zr]Zr-DFO-F8 exhibits powerful tumor delineation in preclinical tumor delineation across TNBC molecular subtypes in vivo.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143847088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Cancer Recurrence Due to Isolated Testicular Metastases Detected by PSMA PET/CT","authors":"Mateus de Oliveira Taveira, Ali Aria Razmaria, Heiko Schoder, Randy Yeh","doi":"10.2967/jnumed.124.269361","DOIUrl":"https://doi.org/10.2967/jnumed.124.269361","url":null,"abstract":"<p>Prostate cancer is the most common solid malignancy to metastasize to the testicles, although testicular metastases remain rare and are often discovered only postmortem. <strong>Methods:</strong> Retrospective analysis of 95 ⁶⁸Ga-prostate-specific membrane antigen (PSMA) PET/CT reports from September 2016 to July 2024 using scrotal region search terms identified 30 patients with indeterminate findings and 6 patients with pathology-confirmed testicular metastases. Data on imaging, pathology, clinical outcomes, and prostate-specific antigen values were reviewed. <strong>Results:</strong> ⁶⁸Ga-PSMA PET/CT detected isolated testicular metastases in 6 patients with M0 castrate-sensitive prostate cancer after maximal pelvic therapy who were imaged because of rising prostate-specific antigen levels. Three of the 6 patients did not have ultrasound abnormalities. Five of the 6 patients were treated with orchiectomy and had durable responses (median follow-up, 33 mo; range, 10–58 mo). <strong>Conclusion:</strong> Including the testes in field of view of the PSMA PET scan may avoid false-negative results. ⁶⁸Ga-PSMA–avid testicular and peritesticular lesions may indicate metastasis even with a negative ultrasound. Orchiectomy can result in durable remissions for these patients.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143819984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of an Ultra-Low-Dose PET Scan Protocol with CT-Based and LSO-TX–Based Attenuation Correction Using a Long–Axial-Field-of-View PET/CT Scanner","authors":"Hasan Sari, Mohammadreza Teimoorisichani, Marco Viscione, Clemens Mingels, Robert Seifert, Kuangyu Shi, Michael Morris, Eliot Siegel, Babak Saboury, Thomas Pyka, Axel Rominger","doi":"10.2967/jnumed.124.268380","DOIUrl":"https://doi.org/10.2967/jnumed.124.268380","url":null,"abstract":"<p>Long–axial-field-of-view (LAFOV) PET scanners enable substantial reduction in injected radiotracer activity while maintaining clinically feasible scan times. Whole-body CT scans performed for PET attenuation correction can significantly add to total radiation exposure. We investigated the feasibility of an ultra-low-dose PET protocol and the application of a CT-less PET attenuation correction method (lutetium oxyorthosilicate background transmission [LSO-TX]) that uses ¹⁷⁶Lu background radiation from detector scintillators with low-count PET data. <strong>Methods:</strong> Each of the 4 study subjects was scanned for 90 min using an ultra-low-dose ¹⁸F-FDG protocol (injected activity, 6.7–9.0 MBq) with an LAFOV PET scanner. PET images were reconstructed with different frame durations using low-dose CT-based and LSO-TX–based attenuation maps (μ-maps). The image quality of PET images was assessed by the signal-to-noise ratio (SNR) in the liver and the contrast-to-noise ratio in the brain. Absolute errors in SUVs between PET images reconstructed with LSO-TX–based and CT-based μ-maps were assessed at each scan duration. <strong>Results:</strong> Visual assessment showed that 20–30 min of PET data obtained using ¹⁸F-FDG activities below 10 MBq (i.e., 0.1 MBq/kg) can yield high-quality images. PET images reconstructed with CT-based and LSO-TX–based μ-maps had comparable SNRs and contrast-to-noise ratios at all scan durations. The mean ± SD SNRs of PET images reconstructed with the CT-based and the LSO-TX–based μ-maps were 9.2 ± 1.9 dB and 9.8 ± 2.0 dB at 90-min scan duration, 6.8 ± 1.7 dB and 6.9 ± 1.8 dB at 30-min scan duration, and 5.5 ± 1.2 dB and 5.6 ± 1.2 dB at 20-min scan duration, respectively. The relative absolute SUV errors between PET images reconstructed with LSO-TX–based and CT-based μ-maps ranged from 3.1% to 6.4% across different volumes of interest with a 20-min scan duration. <strong>Conclusion:</strong> PET scans with an LAFOV scanner maintained good visual image quality with ¹⁸F-FDG activities below 10 MBq for scan durations of 20–30 min. The LSO-TX–based attenuation correction method yielded images comparable to those obtained with the CT-based attenuation correction method in such protocols.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"218 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143819982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An External, Independent Validation of an O-(2-[18F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma","authors":"Nathaniel Barry, Jake Kendrick, Pejman Rowshanfarzad, Ghulam Mubashar Hassan, Roslyn J. Francis, Nicholas Bucknell, Eng-Siew Koh, Andrew M. Scott, Martin A. Ebert, Robin Gutsche, Keith George Ciantar, Norbert Galldiks, Karl-Josef Langen, Philipp Lohmann","doi":"10.2967/jnumed.124.268925","DOIUrl":"https://doi.org/10.2967/jnumed.124.268925","url":null,"abstract":"<p>The goal of this study was to conduct an external, independent validation of an <em>O</em>-(2-[¹⁸F]fluoroethyl)-<span>l</span>-tyrosine ([¹⁸F]FET) PET automatic segmentation network on a cohort of patients with glioblastoma. <strong>Methods:</strong> Twenty-four patients with glioblastoma were included in this study who underwent a total of 52 [¹⁸F]FET PET scans (preradiotherapy, <em>n</em> = 23; preradiotherapy retest, <em>n</em> = 9; follow-up, <em>n</em> = 20). Biologic tumor volume (BTV) delineation was performed by an expert nuclear medicine physician and an automatic segmentation network. Physician and automated quantitative metrics (BTV, mean tumor-to-background ratio [TBR_mean], lesion SUV_mean, and background SUV_mean) were assessed with Pearson correlation and Bland–Altman analysis (bias, limits of agreement [LoA]). Automated and physician segmentation overlap was assessed with spatial and distance-based metrics. <strong>Results:</strong> BTV and TBR_mean Pearson correlation was excellent for all time points (range, 0.92–0.98). In 2 patients with frontal lobe lesions, the network segmented the transverse sinus. Bland–Altman analysis showed network underestimation of physician-derived BTVs (absolute bias, 2.7 cm³, LoA, −13.1–18.5 cm³; relative bias, 27.9%, LoA, −95.3%–151.2%) and deviations for TBR_mean were small (absolute bias, 0.03, LoA, −0.25–0.30; relative bias, 0.83%, LoA −14.27%–15.93%). Median Dice similarity coefficient, surface Dice similarity coefficient, Hausdorff distance, 95th percentile Hausdorff distance, and mean absolute surface distance were 0.83, 0.95, 10.94 mm, 3.62 mm, and 0.88 mm, respectively. <strong>Conclusion:</strong> Automated quantitative analysis was highly correlated with physician assessment; however, volume underestimation and erroneous segmentations may impact radiotherapy treatment planning and response assessment. Further training on a representative local dataset would likely be required for multicenter implementation.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"212Bi-Macroaggregated Albumin Inhibited Mouse Melanoma Growth by Regulating Cell Cycle Checkpoint Markers Without Promoting Living Cell Repopulation","authors":"Satyendra Kumar Singh, Nathan Kauffman, Isabelle Maria Lynch, Zeynep Meral Kunt, Kurt R. Zinn, Dalen Agnew, Jinda Fan","doi":"10.2967/jnumed.124.269190","DOIUrl":"https://doi.org/10.2967/jnumed.124.269190","url":null,"abstract":"<p>Radiotherapy using an α-particle emitting radionuclide has emerged as a promising candidate for cancer treatment; however, the efficacy of ²¹²Bi for mouse melanoma treatment has not yet been studied. Here, we evaluated the efficacy of ²¹²Bi-labeled macroaggregated albumin (MAA) in delivering radiation to mouse melanoma cells in vitro and in vivo. <strong>Methods:</strong> The efficacy of ²¹²Bi efficacy in killing melanoma cells was assessed by in vitro clonogenic and cell survival assays. Immunoblot assays were used to investigate downstream pathways, radioresistance, and epithelial-to-mesenchymal markers. We assessed melanoma cells’ repopulation using a conditioned medium (CM; 50%) from ²¹²Bi-MAA–irradiated B16F10 cells. ²¹²Bi-MAA was intratumorally injected in B16F10 melanoma–bearing C57BL/6 mice to study the efficacy, stability, and internal organ toxicity of ²¹²Bi-MAA. <strong>Results:</strong> ²¹²Bi-MAA effectively killed and inhibited the clonogenic capacity of B16F10 cells. Furthermore, ²¹²Bi-MAA induced the expression of DNA damage (γH2AX) and cell death (cleaved caspase-3) markers, which was at maximum at a dose of 3.7 MBq. Cell cycle checkpoint markers (ATR, Chk1, and Wee1) were also elevated after ²¹²Bi treatment; however, these were reduced at 3.7 MBq compared with 0.93- and 1.85-MBq doses. Minimal to no upregulation of radioresistance (Trex1 and STAT1), cancer stemness (Nanog), and epithelial–mesenchymal transition (E-cadherin, N-cadherin, and Vimentin) markers was found after ²¹²Bi-MAA treatment. CM from ²¹²Bi-MAA–irradiated B16F10 cells did not alter the cell proliferation, colony-forming, and migration capacity of living B16F10 cells. CM did not change epithelial–mesenchymal transition and cell proliferation marker expression. Studies in mice showed that ²¹²Bi-MAA was retained in B16F10 tumors and effectively reduced tumor growth in vivo without causing toxicity. <strong>Conclusion:</strong> These findings suggested that ²¹²Bi-MAA was an effective therapy for mouse melanoma and did not induce factors that aid melanoma repopulation.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validating the Utility of Supervised Clustering Algorithm for Precise [11C]DPA-713 PET Brain Image Quantification","authors":"Youjin Lee, Thanh D. Nguyen, Yong Du, Jennifer M. Coughlin, Sara A. Zein, Nicolas A. Karakatsanis, Sadek Nehmeh, Martin G. Pomper, Susan A. Gauthier, Yeona Kang","doi":"10.2967/jnumed.124.268519","DOIUrl":"https://doi.org/10.2967/jnumed.124.268519","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.268519absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"216 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}